title: Analytical characterization of an orally-delivered peptide pharmaceutical product.
abstract: The characterization of orally-delivered peptide pharmaceuticals presents several challenges to analytical methods in comparison to characterization of conventional small-molecule drugs. These challenges include the analysis and characterization of difficult-to-separate impurities, secondary structure, the amorphous solid-state form, and the integrity of enteric-coated drug delivery systems. This work presents the multidisciplinary analytical characterization of a parathyroid hormone (PTH) peptide active pharmaceutical ingredient (API) and an oral formulation of this API within enteric-coated sucrose spheres. The analysis of impurities and degradation products in API and formulated drug product was facilitated by the development of an ultrahigh-performance liquid chromatography (UHPLC) method for analysis by high-resolution mass spectrometry (MS). The use of UHPLC allowed for additional resolution needed to detect impurities and degradation products of interest. The secondary structure was probed using a combination of solution-state NMR, infrared, and circular dichroism spectroscopic methods. Solid-state NMR is used to detect amorphous API in a nondestructive manner directly within the coated sucrose sphere formulation. Fluorescence and Raman microscopy were used in conjunction with Raman mapping to show enteric coating integrity and observe the distribution of API beneath the enteric-coating on the sucrose spheres. The methods are combined in a multidisciplinary approach to characterize the quality of the enteric-coated peptide product.
authors.affiliation: Biopharmaceutical R&D, GlaxoSmithKline llc., King of Prussia, Pennsylvania 19406, United States.
authors.forename: Wayne P
authors.initials: WP
authors.lastname: Kelley
authors.forename: Shujun
authors.initials: S
authors.lastname: Chen
authors.forename: Philip D
authors.initials: PD
authors.lastname: Floyd
authors.forename: Ping
authors.initials: P
authors.lastname: Hu
authors.forename: Shiva G
authors.initials: SG
authors.lastname: Kapsi
authors.forename: Alireza S
authors.initials: AS
authors.lastname: Kord
authors.forename: Mingjiang
authors.initials: M
authors.lastname: Sun
authors.forename: Frederick G
authors.initials: FG
authors.lastname: Vogt
mesh_terms: D000284:Administration, Oral; D000595:Amino Acid Sequence; D002851:Chromatography, High Pressure Liquid; D004339:Drug Compounding; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D013058:Mass Spectrometry; D008969:Molecular Sequence Data; D010281:Parathyroid Hormone / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D010455:Peptides / Q000032:analysis*; D017433:Protein Structure, Secondary; D011994:Recombinant Proteins / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D013059:Spectrum Analysis, Raman; D013395:Sucrose / Q000737:chemistry
chemical_list: D010281:Parathyroid Hormone; D010455:Peptides; D011994:Recombinant Proteins; D013395:Sucrose